Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Public health policy

4334 - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval


20 Oct 2018


Poster Discussion session - Public health policy


Bioethical Principles and GCP

Tumour Site


Maria Borrell Puy


Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297


M. Borrell Puy1, C. Molto Valiente1, K. Vokinger2, T. Hwang3, A. Ocana Fernandez4, A.J. Templeton5, B. Seruga6, I. Gich Saladich7, A. Barnadas1, E. Amir8, A. Tibau1

Author affiliations

  • 1 Oncology Department, Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, 8026 - Barcelona/ES
  • 2 Medicine, University of Zurich Hospital, 8091 - Zurich/CH
  • 3 Program On Regulation, Therapeutics, And Law (portal), Brigham and Women's Hospital and Harvard Medical School, 2115 - Boston/US
  • 4 Medical Oncology, Complejo Hospitalario Universitario de Albacete, 2006 - Albacete/ES
  • 5 Medical Oncology, St. Claraspital AG, 4058 - Basel/CH
  • 6 Medical Oncology, Institute of Oncology Ljubljana, 1000 - Ljubljana/SI
  • 7 Epidemiology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 8 Department Of Medical Oncology, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4334


AA and CMA regulations were established by the US FDA and EMA, respectively, to improve access to drugs for life-threatening diseases. Here, we evaluate the magnitude of clinical benefit as measured by European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in trials supporting AA and CMA and confirmatory trials supporting conversion to regular approval (RA).


We searched the FDA and EMA websites to identify anticancer drugs that had received AA (since December 1992) or CMA (since March 2006) until December 31, 2017, and to assess the status of conversion to RA. Drug labels and reports of trials were reviewed to apply ESMO-MCBS v1.1. Substantial benefit was defined as a grade of A or B for trials of curative intent and 4 or 5 for those of palliative intent. Agreement between ESMO-MCBS grades for AA/CMA and RA was assessed using Cohen’s κ statistic.


AA was granted for 52 indications based on 64 trials; 61% were subsequently converted to RA based on 36 trials. The median time between AA and RA was 2.8 years. Confirmatory trials were still not completed for 19 (37%) indications. ESMO-MCBS v1.1 was applied to 55 (85%) trials supporting AA and 16% showed substantial benefit. ESMO-MCBS v1.1 could be applied to 30 (83%) trials supporting conversion to RA and 63% showed substantial benefit. CMA was granted for 14 indications based on 15 trials. Only 20% of trial supporting CMA showed substantial benefit. 7 (50%) indications initially receiving CMA were converted to RA (median=4.1y). ESMO-MCBS v1.1 could be applied to 8 trials supporting conversion to RA and 50% showed substantial benefit. Among studies that we could calculate ESMO scores for both RA and AA/CMA, grades were identical for 18/27 cases (κ = 0.40) for AA and 5/8 for CMA (κ = 0.25).


A minority of trials supporting AA and CMA meet the criteria for substantial benefit using ESMO-MCBS. However, among trials supporting conversion to RA, more than half showed substantial benefit. There is only fair concordance in ESMO-MCBS scores between initial and confirmatory studies.

Clinical trial identification

Legal entity responsible for the study

Hospital de la Santa Creu i Sant Pau.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.